Drug Profile
RVT 802
Alternative Names: Allogeneic cultured postnatal thymus-derived tissue - Sumitomo Pharma America; Allogeneic processed thymus tissue-agdc; RETHYMIC; RVT-802Latest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator Duke University
- Developer Duke University; Sumitomo Pharma
- Class
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed DiGeorge syndrome
Most Recent Events
- 06 Dec 2022 Altavant Sciences has been merged with Enzyvant to form Enzyvant
- 31 Mar 2022 Launched for DiGeorge syndrome in USA (Parenteral) in March 2022 - First global launch (Sumitomo Pharma pipeline, May 2022)
- 08 Oct 2021 Registered for DiGeorge syndrome in USA (Parenteral) - First Global approval